DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Provencher, S. J.
Right arrow Articles by Gascon-Barré, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Provencher, S. J.
Right arrow Articles by Gascon-Barré, M.

Vol. 27, Issue 4, 449-455, April 1999

Effect of Cyclosporine A on Cytochrome P-450-Mediated Drug Metabolism in the Partially Hepatectomized Rat

Sébastien J. Provencher, Christian Demers, Marie-Claude Bastien, Jean-Pierre Villeneuve, and Marielle Gascon-Barré

Centre de recherche (S.J.P., C.D., M.C.B., J.P.V., M.G.B.), Centre hospitalier de l'Université de Montréal, Campus Saint-Luc; and Départements de pharmacologie (S.J.P., M.C.B., J.P.V., M.G.B.) and médecine (J.P.V.), Faculté de médecine, Université de Montréal, Montréal, Québec, Canada

Despite its hepatotoxic potential, cyclosporine A (CsA) has been reported to positively influence compensatory liver growth. To probe the physiological consequences of CsA on the recovery of liver function, studies were initiated in the 2/3 partially hepatectomized (PHx) rat, taking the recovery of cytochromes P-450-dependent drug metabolism as primary outcome. CsA was administered at a dose of 3.33 mg/kg/day for 10 days. Drug metabolism was evaluated by the recovery of 14CO2 after administration of isotopically labeled model drugs and by studying the expression of the P-450 transcripts involved in their biotransformation before and 24 to 96 h after PHx. Before PHx, neither the steady-state mRNA nor the in vivo disposition of caffeine (CYP1A2), erythromycin (CYP3A2 and 3A1), or aminopyrine (CYP2B1 and 2C11) were influenced by CsA. Studies 24 h after PHx revealed a 29 to 39% reduction in the elimination of [14C]aminopyrine and [14C]erythromycin, which was unaffected by CsA. Their metabolism at 48 to 96 h after PHx also remained unaffected by CsA. By contrast, postPHx, [14C]caffeine elimination decreased to a level closely proportional to the loss in liver mass. In addition, CsA accelerated the recovery and/or prevented the decrease of caffeine elimination 24 h after PHx but not at later time points, indicating an early, but unsustained, beneficial effect of CsA on the recovery of CYP1A2-mediated activities. These data show that at the critical time of greatest loss in liver mass, CsA has only a selective influence on the biotransformation of cytochrome P-450 protein-dependent activities and that its effect on the regeneration process does not translate into an overall accelerated recovery of the hepatic drug-metabolizing function.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Theodoropoulos, C. Demers, J.-L. Petit, and M. Gascon-Barre
High sensitivity of rat hepatic vitamin D3-25 hydroxylase CYP27A to 1,25-dihydroxyvitamin D3 administration
Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E138 - E147.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. J. Provencher and M. Gascon-Barre
Effect of Cyclosporine A on Hepatic Compensatory Growth: Role of Calcium Status
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 58 - 65.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Theodoropoulos, C. Demers, A. Mirshahi, and M. Gascon-Barre
1,25-Dihydroxyvitamin D3 downregulates the rat intestinal vitamin D3-25-hydroxylase CYP27A
Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E315 - E325.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.